ASCP Pathology Trailblazers in HER2-low Breast Cancer

ASCP, working in collaboration with Q Synthesis LLC, invites pathologists to participate in a unique cohort-based leadership development CME program called Pathology Trailblazers: HER2-low Breast Cancer Collaborative Learning Exchange.

This program will begin in May 2022 and run for approximately 3 months. 

Pathology Trailblazers: HER2-low Breast Cancer Collaborative Learning Exchange is designed to:

• Strengthen leadership skills among pathologists
• Increase knowledge and competence around the evolving landscape of HER2-low breast cancer
• Improve how HER2 testing is performed, classified, and reported
• Support the dissemination and implementation of best practices around HER2 testing and reporting in breast cancer

Learn more about this unique program here: ​https://www.ascp.org/content/learning/breast-cancer#trailblazers